Golden Ear

Metadata

Regulatory Status

China

• Traditional food use: Long-established history of consumption as an edible and medicinal mushroom in China, valued as a premium food product.
• Dual-use status: Recognized as both an edible fungus and a traditional medicinal food in Chinese practice.
• Cosmetic ingredient registration: In February 2025, N. aurantialba was officially registered as a new cosmetic ingredient in China, with multiple chemical components approved for use as cosmetic additives. This registration signals regulatory recognition of the species’ skin-active properties.
• Chinese Pharmacopoeia: Not listed as an official drug in the Chinese Pharmacopoeia, unlike its better-known relative Tremella fuciformis (Bai Mu Er).
• Commercial cultivation: Cultivated commercially in China, primarily in Yunnan, Sichuan, and other southwestern provinces. Known as Jin Er (金耳) and cultivated at commercial scale.
• Traditional medicinal claims: Ancient Chinese texts cite benefits for liver protection and efficacy in alleviating cough and phlegm.

United States

• Dietary supplement: Not marketed as a dietary supplement in the US market. Occasionally available in dried form through Asian specialty food retailers.
• FDA GRAS status: No GRAS determination.

European Union

• Novel food: No specific authorization. Would likely require novel food authorization for supplement or concentrated extract forms, as it lacks a significant history of consumption in the EU before May 1997.
• Cosmetic use: Not registered in the EU cosmetic ingredient database (CosIng) as of this writing.

Japan and Korea

• Japan: Not recognized in the Japanese Pharmacopoeia or as an approved health food ingredient.
• Korea: Not widely commercialized. Available as a specialty food product in limited quantities.

Conditions & Indications

Primary: Skin Hydration and Photoprotection (Preclinical Evidence)

• Moisture retention and aquaporin promotion: Degradation products of N. aurantialba polysaccharides (NAPs) significantly promote the synthesis of aquaporin in epidermal keratinocytes, enhancing transcellular water transport and demonstrating good water absorption and retention properties. This mechanism parallels the moisture-retention properties of the closely related Tremella fuciformis polysaccharides.
• UV photoprotection: N. aurantialba extract (TAE) significantly enhanced the survival rate of UVB-irradiated HaCaT keratinocytes, promoted cell migration (increasing migration rates above 50%), and reduced reactive oxygen species (ROS) levels in vitro. In vivo, TAE suppressed abnormal epidermal thickening and mast cell infiltration induced by UVA/UVB in mouse dorsal skin, and facilitated restoration of collagen fiber integrity.
• Anti-photoaging: Basidiospore polysaccharides exhibited antioxidant and anti-inflammatory effects against UVB-induced damage in L929 fibroblast cells, providing photoprotective benefits at the cellular level.

Secondary: Hypoglycemic Activity (Preclinical Evidence)

• Adjunctive hypoglycemic effect: A purified polysaccharide (NAP-3, molecular weight 428 kDa) exhibited alpha-glucosidase inhibitory activity comparable to acarbose in vitro. When combined with metformin in diabetic mice, NAP-3 significantly reduced blood glucose levels, body weight, serum insulin levels, and glucose intolerance while increasing antioxidant enzyme levels. This suggests potential as an adjunctive agent for type 2 diabetes management.

Secondary: Immunomodulatory Activity (Preclinical Evidence)

• TLR4-mediated macrophage activation: The glucuronoxylomannan TAP-3 extracted from fruiting bodies significantly stimulated macrophage production of nitric oxide (NO), IL-1beta, and TNF-alpha. The mechanism involves toll-like receptor 4 (TLR4) on the macrophage surface, providing a defined molecular pathway for immune activation.

Emerging: Antitumor and Anti-inflammatory (Preclinical)

• Antitumor activity via immune modulation: Crude polysaccharides from fruiting bodies exhibited no direct cytotoxicity against cancer cell lines but extended the lifespan of Sarcoma 180-inoculated mice by 11.1% to 66.7%. The antitumor mechanism appears to operate through immune response enhancement rather than direct cytotoxicity.
• Anti-inflammatory activity: NAPs demonstrate anti-inflammatory effects in preclinical models, reducing pro-inflammatory mediators and oxidative stress markers.
• Gut microbiota modulation: Polysaccharides modulate intestinal flora composition, potentially contributing to metabolic and immune health through prebiotic-like effects.
• Lipid-lowering activity: Preclinical evidence suggests lipid-lowering effects, though specific mechanisms and dosing remain under investigation.
• Anticoagulant activity: Some polysaccharide fractions demonstrate anticoagulant properties in vitro, though clinical relevance is undetermined.

Mechanism of Action

Primary Mechanisms

1. Polysaccharide-driven skin hydration: NAPs form a hydrophilic polysaccharide film on the skin surface and within the stratum corneum, retaining moisture through hydrogen bonding with water molecules. More importantly, NAP degradation products promote aquaporin-3 (AQP3) expression in keratinocytes, enhancing active transcellular water transport. This dual mechanism — passive moisture retention and active aquaporin promotion — provides a more comprehensive hydration effect than simple humectant activity.

2. Photoprotective ROS scavenging: NAPs scavenge UV-generated reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl radicals) through their polyhydroxyl structure, reducing oxidative damage to cellular membranes, proteins, and DNA. This antioxidant defense is complemented by upregulation of endogenous antioxidant enzymes (SOD, catalase) and suppression of UV-induced inflammatory signaling (NF-kB, COX-2).

3. TLR4-dependent immunomodulation: Glucuronoxylomannan polysaccharides from N. aurantialba function as TLR4 agonists, activating the MyD88/NF-kB signaling cascade in macrophages. This stimulates innate immune responses including phagocytosis, NO production, and pro-inflammatory cytokine release (TNF-alpha, IL-1beta, IL-6). The specificity for TLR4 distinguishes this mechanism from beta-glucan signaling through dectin-1.

Secondary Mechanisms

• Alpha-glucosidase inhibition: NAP-3 polysaccharides inhibit alpha-glucosidase, the intestinal enzyme that cleaves oligosaccharides into absorbable monosaccharides, thereby slowing postprandial glucose absorption. This is the same mechanism employed by the pharmaceutical drug acarbose.
• Collagen fiber restoration: In UV-damaged skin, NAPs facilitate the reorganization and restoration of collagen fiber architecture, potentially through modulation of matrix metalloproteinase (MMP) activity and stimulation of fibroblast collagen synthesis.
• Carotenoid antioxidant activity: The golden-yellow carotenoid pigments contribute additional lipophilic antioxidant capacity through singlet oxygen quenching and peroxyl radical scavenging.

Structural Comparison with Tremella fuciformis

N. aurantialba polysaccharides share the glucuronoxylomannan backbone characteristic of Tremellomycetes polysaccharides, consisting primarily of beta-1,3-D-mannopyranose with beta-1,2 branching and glucuronic acid and xylose substituents. This structural similarity to Tremella fuciformis glucuronoxylomannan suggests comparable moisture-retention and immunomodulatory properties, though quantitative differences in branching patterns, molecular weight, and substituent ratios may account for species-specific bioactivity differences. The additional carotenoid content in N. aurantialba provides photoprotective capacity not present in the white-colored T. fuciformis.

Clinical Evidence Summary

No human clinical trials have been published for Naematelia aurantialba for any therapeutic or cosmetic indication. All evidence is derived from in vitro studies and animal models.

Preclinical Evidence (Selected)

Evidence Limitations

• No human clinical trials have been published for any indication — skin hydration, photoprotection, hypoglycemia, or immune modulation.
• All skin hydration and photoprotection evidence comes from in vitro keratinocyte/fibroblast studies and UV-irradiated mouse models. Translation to human cosmetic or dermatological endpoints is uncertain.
• The alpha-glucosidase inhibitory activity of NAP-3 was demonstrated in vitro and in a single animal study; human pharmacokinetic and efficacy data are entirely lacking.
• The cosmetic ingredient registration in China (2025) reflects regulatory acceptance of safety and traditional use rather than clinical efficacy data.
• Species identification within the Naematelia aurantialba complex can be challenging, and recent phylogenetic studies have revealed previously unrecognized species diversity in southwestern China.
• Bioactive compound concentrations may vary significantly with cultivation substrate, growing conditions, and post-harvest processing.

Safety Profile

General Assessment

N. aurantialba has a long history of traditional consumption as a food mushroom in China, with no documented toxicity at normal culinary intake levels. It is commercially cultivated and widely available in Chinese markets. The 2025 cosmetic ingredient registration in China implies safety assessment for topical application. No systematic safety studies of concentrated oral extracts have been published.

Contraindications

• Fungal allergy: Individuals with known allergy to Tremellomycetes or related jelly fungi should exercise caution.
• Immunocompromised patients: TLR4-mediated immunomodulatory activity raises theoretical concerns for immunocompromised individuals, though no specific evidence of harm exists.

Drug Interactions

• No documented drug interactions.
• Theoretical: The alpha-glucosidase inhibitory activity of NAP-3 could theoretically potentiate the effects of acarbose, miglitol, or other alpha-glucosidase inhibitors if consumed concurrently in concentrated extract form. The anticoagulant activity of some polysaccharide fractions raises theoretical concern for concurrent use with anticoagulant medications.

Side Effects

• Common: None documented at culinary consumption levels.
• Uncommon: Allergic reactions possible in individuals with fungal sensitivities.
• Theoretical: Concentrated polysaccharide extracts with immunostimulatory activity could theoretically exacerbate autoimmune conditions, though this has not been observed.

Quality Concerns

• Species authentication is important, as the N. aurantialba complex has been shown to contain previously unrecognized species in recent phylogenetic studies. DNA barcoding may be necessary for definitive identification.
• Cultivation substrate quality affects heavy metal content and bioactive profile.
• Post-harvest processing (drying temperature and method) can affect polysaccharide integrity and bioactivity.

Clinical Dosage

No Established Clinical Dosage

No human clinical trials have been conducted, so no evidence-based dosage recommendations exist for N. aurantialba for any therapeutic indication.

Traditional Culinary Use

• Typical preparation: Dried fruiting bodies are rehydrated and used in soups, dessert soups (tang shui), and stews in Chinese cuisine
• Typical serving: 5—15 g dried mushroom per serving (rehydrates to approximately 5—10 times dry weight)
• Preparation: Typically simmered in water or broth for 1—2 hours; the gelatinous texture is valued both culinarily and for its mucilaginous polysaccharide content

Dried Mushroom Powder (Estimated Nutritional Supplement Use)

• Estimated intake: 3—6 g/day of dried mushroom powder
• Note: No clinical trial data to support specific therapeutic dosing

Topical/Cosmetic Application

• Cosmetic ingredient concentration: Per the 2025 Chinese cosmetic ingredient registration; specific permitted concentrations would be defined by manufacturers within regulatory guidelines
• Polysaccharide extract: Applied as an active ingredient in serums, creams, and masks for moisture retention and photoprotection
• Note: Topical bioavailability and optimal concentrations for cosmetic efficacy have not been established in published clinical trials

Comparison with Tremella fuciformis Dosing

• Tremella fuciformis is typically dosed at 3—10 g dried fruiting body per day in traditional use and dietary supplementation
• Similar dosing ranges may be reasonable for N. aurantialba given the structural similarity of the polysaccharide profiles, but this is speculative

Sources

• Zhang Y, Li H, Wang X, et al. Protective and reparative effects of Tremella aurantialba extract against skin photoaging and its underlying mechanisms. J Cosmet Dermatol. 2025;24(2):e16714
• Li X, Chen Y, Wang J, et al. Functional characterization of Naematelia aurantialba basidiospore polysaccharides in L929 cells: photoprotective, antioxidant, and anti-inflammatory effects against UVB-induced damage. Foods. 2025;15(3):598
• Chen H, Xu J, Li Y, et al. A polysaccharide NAP-3 from Naematelia aurantialba: structural characterization and adjunctive hypoglycemic activity. Carbohydr Polym. 2023;318:121096
• Du B, Zhu F, Xu B. Isolation, structures, bioactivities, application and future prospective for polysaccharides from Tremella aurantialba: a review. Front Immunol. 2022;13:1091210
• Wang Y, Zhang L, Zhao M, et al. Purification, structural characteristics, bioactive properties, and applications of Naematelia aurantialba polysaccharides: a comprehensive review. Molecules. 2025;30(20):4073
• Zhu M, Xu Y, Li H, et al. GSP-2, a polysaccharide extracted from Ganoderma sinense, is a novel toll-like receptor 4 agonist. PLoS One. 2019;14(8):e0221027
• He Y, Li X, Chen Y, et al. Naematelia aurantialba: a comprehensive review of its biological activities, nutritional composition, and application potential. Food Med Homol. 2025;2:9420072
• Yang L, Zhang X, Millanes AM, Wedin M, et al. Phylogeny and taxonomy of the Naematelia aurantialba complex in southwestern China. J Fungi. 2024;10(12):845
• Ma Z, Wang J, Zhang L, et al. Adaptive laboratory evolution of Naematelia aurantialba under high temperature for efficient production of exopolysaccharide. Int J Biol Macromol. 2024;277:134128
• Bandoni RJ, Zang M. On an undescribed Tremella from China. Mycologia. 1990;82(1):125-127

Connections

• Tremella fuciformis (Snow Fungus): Tremella is the closest medicinal relative and the most direct comparator. Both are gelatinous Tremellomycetes with glucuronoxylomannan polysaccharides that provide moisture retention and skin hydration properties. T. fuciformis has a longer research history and established TCM pharmacopoeia status. N. aurantialba may offer additional photoprotective benefits from its carotenoid content, positioning it as the “photoprotective upgrade” to Snow Fungus for sun-exposed skin applications.
• Auricularia auricula-judae (Wood Ear): Wood Ear is another jelly fungus with polysaccharide-driven bioactivity, particularly anticoagulant and cardiovascular effects. The gelatinous texture and polysaccharide richness are shared characteristics of these fungi, though their bioactive profiles and primary indications differ.
• Reishi (Ganoderma lucidum): Reishi provides complementary immune modulation through both polysaccharide and triterpenoid mechanisms. Traditional Chinese medicine formulations combining immune-modulating and beauty-supporting mushrooms have historical precedent.
• Cosmeceutical mushroom category: N. aurantialba joins Tremella as a polysaccharide-rich mushroom positioned primarily for skin health applications. The cosmetic ingredient registration in China (2025) represents a regulatory milestone that may accelerate research and product development, potentially advancing the evidence base beyond the current preclinical stage.
• Traditional Chinese food-medicine context: In Chinese culinary-medicinal tradition, N. aurantialba occupies a premium position similar to that of T. fuciformis but at a higher price point, reflecting both its relative rarity and its perceived superior quality. The golden color (associated with the spleen/earth element in five-element theory) distinguishes it from the white Snow Fungus and may contribute to traditional attribution of different therapeutic properties.